KD025: Phase II started

Kadmon began the open-label, U.S. Phase II Study 206 to evaluate 200 mg

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE